<DOC>
	<DOCNO>NCT00163267</DOCNO>
	<brief_summary>The Mirror Study randomize , double-blinded mono-centre trial access periinterventinal postinterventional administration clopidogrel patient peripheral vascular disease .</brief_summary>
	<brief_title>Mirror Trial - Follow-Up Management Peripheral Arterial Intervention With Clopidogrel</brief_title>
	<detailed_description>Clopidogrel approve secondary prevention atherosclerosis patient peripheral vascular disease . Currently data amount platelet activation peripheral arterial intervention , effect clopidogrel platelet adhesion clinical impact . Patients chronic peripheral arterial disease receive placebo clopidogrel intervention 6 month follow-up . Platelet activation , effect macro-and microcirculation assess well clinical endpoint .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Peripheral arterial disease require intervention Patient already coumadin clopidogrel Acute onset PVD symptoms Patient require operation Contraindication aspirin clopidogrel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>peripheral arterial intervention</keyword>
	<keyword>atherosclerosis</keyword>
	<keyword>platelet</keyword>
	<keyword>Age 18</keyword>
</DOC>